Publication Name	World Journal of Gastroenterology
Manuscript ID	5848
Country	United States

Received	2013-09-28 15:44
Peer-Review Started	2013-09-29 12:22
To Make the First Decision	2013-10-22 16:35
Return for Revision	2013-10-23 11:00
Revised	2013-10-25 05:29
Second Decision	2013-11-13 12:03
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-11-13 15:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-01-20 09:55
Publish the Manuscript Online	2014-03-12 14:46

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Hepatic inflammation and progressive liver fibrosis in chronic liver disease
Manuscript Source	Invited Manuscript
All Author List	Albert J Czaja
Funding Agency and Grant Number
Corresponding Author	Albert J Czaja, MD, Professor Emeritus of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, United States. czaja.albert@mayo.edu
Key Words	Inflammation; Fibrosis; Cirrhosis; Treatment; Anti-oxidants; Angiotensin receptors; Investigational drugs
Core Tip	The prevention of hepatic fibrosis and the reversal of cirrhosis are now achievable objectives in the management of chronic liver disease. Conventional immunosuppressive, anti-inflammatory, and anti-viral therapies can accomplish these outcomes by reducing liver damage, suppressing hepatic inflammation, and eliminating etiological agents, but they do so inconsistently and indirectly. The continuing clarification of pro-fibrotic mechanisms affords opportunities to design site-specific, anti-fibrotic interventions. Anti-oxidants and angiotensin inhibitors have shown promise as adjunctive anti-fibrotic agents in preliminary human studies, and they exemplify a genre of interventions that are likely to influence future management strategies.
Publish Date	2014-03-12 14:46
Citation	Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20(10): 2515-2532
URL	http://www.wjgnet.com/1007-9327/full/v20/i10/2515.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i10.2515

Full Article (PDF)	WJG-20-2515.pdf
Full Article (Word)	WJG-20-2515.doc
Manuscript File	5848-Review.doc
Answering Reviewers	5848-Answering reviewers.pdf
Copyright License Agreement	5848-Copyright assignment.pdf
Peer-review Report	5848-Peer reviews.pdf
Scientific Editor Work List	5848-Scientific editor work list.doc